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Abstract The dramatic technical advances in methods to
measure gene expression on a genome-wide level thus far
have not been paralleled by breakthrough discoveries in
psychiatric disorders—including major depression (MD)—
usingthesehypothesis-freeapproaches.Inthisreview,wefirst
describe the methodologic advances made in gene expression
analysis, from quantitative polymerase chain reaction to next-
generation sequencing. We then discuss issues in gene
expression experiments specific to MD, ranging from the
choice of target tissues to the characterization of the case
group. We provide a synopsis of the gene expression studies
published thus far for MD, with a focus on studies using
mRNA microarray methods. Finally, we discuss possible new
strategies for the gene expression studies in MD that
circumvent some of the addressed issues.
Keywords Major depression.Gene expression.
mRNA.RNA-Seq
Introduction
The pathophysiology of major depression (MD) and the
mechanism of action of the antidepressant treatments
remain largely obscure. With the sequence of the human
genome being publicly available since February 2001, an
array of novel research tools have become available that
may yield unbiased, hypothesis-free insight into the
pathophysiologic underpinnings of this disorder. This
article focuses on methods investigating disease-related
changes in gene expression at the level of mRNA, the
nucleic acid transcript of gene sequence from which protein
is synthesized in all mammalian cells. We first discuss
methodologic issues for the measurement of gene expres-
sion and factors related to the choice of the investigated
tissue. We then summarize recent publications describing
gene expression changes related to MD and how they may
impact our understanding of the pathophysiology of this
disorder. This discussion sets the stage for other articles in
this journal that describe epigenetic mechanisms, as the
direct consequence of epigenetic changes is a long-lasting
impact at the level of gene transcription to mRNA.
Methods of Determining Gene Expression
The initial step in gene expression is transcription (transfer)
of genetic information contained in genomic DNA to
mRNA. Most of the genetic regulation in humans is
thought to occur at the level of gene transcription. The
objective of gene expression analysis at the transcriptional
level is to determine whether specific mRNA sequences
transcribed from particular genes are present in cells or
tissues of interest, and if so, at what level. Transcripts can
be directly measured as RNA species or can be converted
into cDNA via reverse transcription—a laboratory proce-
dure that uses viral enzymes to transcribe RNA to DNA.
The cDNA copies are amplified using polymerase chain
reaction (PCR), and levels of transcripts within samples in a
particular disease state can be compared with those in
healthy samples to identify transcriptional differences
between the two conditions.
Traditional methods of gene expression analysis included
Northern blots, quantitative PCR (qPCR), real time qPCR,
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DOI 10.1007/s11920-010-0100-3and in situ hybridization, all of which allow profiling of the
transcriptome on a limited scale restricted to single genes or
small groups of genes (Fig. 1). Microarray technologies now
allow parallel analysis of thousands of transcripts across
many samples simultaneously. Expression levels serve as a
surrogate to study the activity of a gene, even though
microarrays only measure steady-state levels and do not
provide information on the type of transcriptional regulation
or post-transcriptional changes. Variation in transcript levels
represents an intermediate stage between DNA sequence
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Methods of gene expression profiling
In situ hybridization is a method of localizing and detecting specific mRNA sequences in morphologically preserved tissue 
sections or cell preparations by hybridizing labelled complementary strands of a nucleotide probe to the sequence of interest at 
elevated temperatures and washing away the excess probe. The labelled probe is then localized and quantified in the tissue 
using autoradiography, fluorescence microscopy, immunohistochemistry, or radioactivity.
In Northern blotting, total RNA/mRNA is size-separated by denaturing agarose gel electrophoresis, the separated RNA is 
transferred onto a nylon membrane, and the RNA is detected by isotopic or nonisotopic labelled probes.
In RNase protection assays, samples are mixed with complementary probes to form double-stranded molecules and exposed 
to ribonucleases that specifically cleave only single-stranded molecules. After the reaction is complete, susceptible RNA regions 
are degraded, and the surviving fragments retain the sequence of interest.
In subtractive hybridization, molecules of one mRNA pool are labelled (driver complementary DNA [cDNA]), and mRNA of 
another pool (tracer cDNA) are hybridized to the cDNA of the first pool, and both labelled cDNA and cDNA/mRNA hybrids are 
immobilized. After several rounds of hybridization and removals by streptavidin precipitation, the differentially expressed genes 
are left at the end.
Reverse transcription polymerase chain reaction (RT-PCR) is a variant of polymerase chain reaction (PCR) that is used to 
amplify small amounts of DNA. RNA strands are reverse transcribed into its DNA complement (cDNA) using the enzyme reverse 
transcriptase, amplified using traditional or real time PCR, visualized on a gel using electrophoresis, and quantified.
Differential display PCR is a modified form of RT-PCR that can track the expression of many genes simultaneously using 
partially degenerate PCR primers in which the choice of the base at some positions is intentionally flexible. The resulting 
amplification patterns result in a complex ladder of bands that are size-fractionated using polyacrylamide gels.
Expression sequence tags (ESTs) involve sequencing several hundred base pairs from ends of cDNA clones taken from a 
cDNA library.
Macroarrays are low-density arrays that preceded microarrays and are, similar to the microarrays, based on the principle of 
hybridization. Probes are usually printed within the pores of nylon membranes. 
5’CAGE (cap analysis of gene expression) involves RNA extraction of five ends of capped transcripts, reverse transcription 
into DNA, PCR amplification, and sequencing to quantify the amount of each transcript.
3’SAGE (serial analysis of gene expression) involves extraction of unique transcript-specific tags, linking of these tags to form 
long serial molecules, cloning and sequencing of these serial molecules, and counting the number of tags of the corresponding 
transcripts for quantization. 
Massively parallel signature sequencing (MPSS) is an open-ended platform that analyzes the level of gene expression in a 
sample by counting the number of individual mRNA molecules produced by each gene. Unique tags allow attachment of 
amplified PCR products to microbeads. After several rounds of ligation-based sequence determination using restriction 
endonucleases, a sequence signature is identified from each bead in parallel. The relative abundance of these signatures in a 
given library represents a quantitative estimate of expression of that gene.
The fundamental principles of microarrays and RNA-Seq are described in detail in the text.
Fig. 1 Timeline of methods in gene expression. The figure shows a spectrum of different techniques used to measure mRNA ranging from
profiling of gene expression on a limited scale to a global scale
136 Curr Psychiatry Rep (2010) 12:135–144differences and complex human traits, thereby providing a
snapshot of the consequences of DNA variance on cellular
processes.
Microarrays function on the principle of complementary
hybridization between nucleic acids (A → T and G → C)
and take advantage of the knowledge of the human genome
sequence [1]. DNA sequences of varying lengths represent-
ing all known genes, and even putative genes are spotted
onto a solid support (eg, glass, metal, nitrocellulose, beads).
A typical high-density microarray contains sequences
complementary to thousands of gene sequences (probes),
each immobilized to a specific spatial coordinate on the
microarray surface. The RNA is extracted from tissues or
cells of interest and labelled with fluorescent tags or
radioactivity. The labelled RNA hybridizes only to the
cDNA sequences on the array, and the signal is proportional
to the abundance of the RNA in the sample. This signal is
detected using autoradiography, chemiluminescence, or
fluorescent scanning. A kinetic analysis allows gene
expression levels to be measured by their positions on the
microarray and level of hybridization (measured by signal
intensity) to be detected for each probe. For data analysis,
signal intensity of each probe is compared between the
experimental groups to determine whether the specific
mRNA of a gene in a group is upregulated, downregulated,
or unaffected compared with the other group. Although
recent methodologic developments have significantly re-
duced the technical problems of microarrays, they are still
hampered by the semiquantitative nature of the measures
and the fact that only currently known genes or splice
variants can be measured.
The completion of the Human Genome Project, together
with advances in sequencing technologies have directed the
emergence of a panel of revolutionary sequencing technol-
ogies termed next-generation sequencing (NGS). Three
NGS platforms currently dominate the market: SOLiD
(Applied Biosystems, Foster City, CA), Genome Analyzer
(Illumina, San Diego, CA) and 454 GS FLX (Roche, Basel,
Switzerland), with more coming in the near future. These
technologies allow generation of three to four magnitudes
more sequence in a cost-effective manner than the
conventional Sanger sequencing method. The fundamental
nature of these systems is the miniaturization of single-
molecule DNA sequencing reactions, allowing optimal
spatial arrangement of each reaction and an efficient
scanning for millions of individual sequences on a standard
glass slide [2].
NGS has already proven successful in de novo sequencing
of genomes, including the giant panda and the sequencing of
total cDNA for transcriptome studies, a method known as
RNA-Seq. The key advantages of RNA-Seq are the com-
bined analysis of accurate, quantitative measurement of gene
expression; unbiased discovery of novel transcribed regions;
and global assessment of alternative splice sites in the
genome, all in a single experiment. In RNA-Seq, a
population of long RNA is converted to a library of cDNA
fragments with adaptor sequences attached to one or both
ends. Depending on the platform, each cDNA molecule with
or without amplification is sequenced in a high-throughput
manner to obtain short sequences of 30 to 400 bp. Following
sequencing, the reads are typically aligned with a reference
genome or transcriptome or assembled de novo to generate a
base-resolution expression map for each gene at the
transcriptional structure level and/or expression level. One
major advantage of RNA-Seq over microarrays, especially
for psychiatric disorders, in which smaller differences in
gene expression are expected between disease and non-
disease tissue, is that because the technique is quantitative,
RNA-Seq sequences every single transcript so that quantifi-
cation is not confounded by the intermediate step of
hybridization, as for microarrays. The wide dynamic range
of RNA-Seq allows robust capture of low expressed
transcripts and makes comparisons of the transcriptome
across different tissues without technical considerations such
as normalization possible. Several challenges of RNA-Seq
include the huge amount of data and bioinformatic analysis,
library preparation biases, and other technical issues (eg,
deep sequencing requirements for enough coverage of
certain low expressed transcripts and low-quality reads and
errors in image analysis). Despite these limitations, with the
surfacing of new projects such as the 1,000 Genomes Project
(http://www.1000genomes.org) and the reduction of
sequencing costs, it is expected that RNA-Seq will soon
surpass microarrays as the gold standard for comprehensive
surveying of transcriptomes.
Choice of Target Tissues for Gene Expression Studies
To obtain meaningful results from gene expression experi-
ments for MD research, one has to carefully consider the
target tissue. Although brain tissue would be the optimal
choice, its use in MD transcriptome experiments is
challenging. Postmortem samples can retain their RNA
quality and intact histologic architecture with careful
processing but may be affected by gene expression changes
accompanying death. In addition, phenotype information
obtained through psychological autopsies can be confounded
by its retrospective nature. This is why many researchers
have investigated MD-related gene expression changes in
peripheral tissue, most often peripheral blood.
Postmortem Human Brain Tissue
Gene expression patterns are likely to undergo recognizable
changes in specific regions of the brain to initiate, sustain,
Curr Psychiatry Rep (2010) 12:135–144 137and/or modify the altered biological states that accompany
behavioral phenotypes, thereby providing an opportunity to
characterize the basis of mental disorders [3].
High-quality mRNA is a prerequisite for all molecular
methods of mRNA profiling. Several groups have pub-
lished detailed guidelines to assist brain banks and
researchers in the processing and freezing of postmortem
brains to ensure high-quality RNA [4]. Some of the factors
influencing RNA quality in postmortem tissue are listed
below, including pH, temperature, and length of the agonal
state. Studies have indicated that below the critical pH
threshold of about 6.8, transcriptional changes in stress
response, apoptosis, and inflammation genes are accelerat-
ed [5]. The length of the agonal state has been shown to
affect transcription, but it is still unclear to what extent
neurons in different layers of the brain exhibit variable
vulnerabilities and if apoptosis and RNA degradation occur
at the same rates during the agonal period.
Another important factor is the selection of the brain
region for analysis. Pierce and Small [6] suggested the use
of brain imaging approaches to select brain regions for
microarray experiments. Many brain structures have been
implicated in the pathophysiology of psychiatric disorders.
However, the available data point to dysregulations that
affect brain circuits that involve several brain regions as
opposed to single brain regions. Changes of expression in
one area may only be disease relevant when accompanied
by changes in other structures in the implicated circuit. This
circuit-based approach, however, poses novel problems for
the already complicated data analysis in expression micro-
array studies. In addition, smaller but relevant changes in a
subpopulation of cells may be diluted and thus not
recognized if a whole region is being analyzed. A
combination of laser capture microscopy (LCM) and
mRNA amplification techniques [7] allows the comparison
of expression changes in single cells.
In addition to these technical considerations, it is
important to carefully match cases and controls for a series
of factors, including age, gender, ethnicity, agonal state,
medications, postmortem interval, laterality of the brain,
and time to processing [8].
Whole Blood, Peripheral Blood Mononuclear Cells,
and Lymphocyte Cell Lines
The main reason for using peripheral blood as a target
tissue to pursue transcriptomic research in MD is that blood
is readily accessible. In addition, peripheral blood cells may
in fact serve as surrogate markers for some of the disease
processes in MD or help characterize disease state even
though they are not likely the cell type causally involved in
the cognitive symptoms of MD. Peripheral blood cells
share more than 80% of the transcriptome with nine tissues:
brain, colon, heart, kidney, liver, lung, prostate, spleen, and
stomach [9], and the expression levels of many classes of
biological processes have been shown to be comparable
between whole blood and prefrontal cortex [10]. Indeed
there is considerable communication between the immune
system and the central nervous system (CNS). Many
cytokine receptors have been located within the CNS, and
interleukin-2 mRNA and T-cell receptors have been
specifically detected in neurons [11]. Lymphocytes also
express several neurotransmitter and hormone receptors,
including dopamine, cholinergic, and serotonergic receptors
and glucocorticoid and mineralocorticoid receptors and
their chaperones [12]. Lymphocytes are directly influenced
by glucocorticoids and catecholamines, and these two
systems are perturbed in MD. Several studies have reported
abnormalities in the immune system of psychiatric patients
[12]. Studying lymphocytes in psychiatric disorders thus
may yield information on disease-specific immune changes,
and changes in lymphocytic immune function may serve as
markers of disease progression. In addition, some receptor
systems may show similar abnormalities in lymphocytes
and the brain. CNS glucocorticoid receptor resistance and
its resolution with antidepressant treatment is one of the
most consistent biological findings in MD [13]. Steroid
resistance also has been reported for the activation of T
cells and monocytes in MD and bipolar disorder, suggest-
ing comparable glucocorticoid receptor impairment in
immune and CNS cells. In addition, genetic polymorphisms
may similarly affect the function of molecules that are
expressed in both lymphocytes and the brain. Binder et al.
[14] reported that polymorphisms in FKBP5, a glucocorti-
coid receptor–regulating co-chaperone of hsp90, are asso-
ciated with increased lymphocytic levels of FKBP5 protein,
as well as an altered response of the stress hormone system,
suggesting that the functional effects of these polymor-
phisms were not limited to immune cells, but also affected
CNS function.
Transcriptional profiles in peripheral blood are highly
sensitive to the collection method and other handling
procedures. Three options are commonly used for transcrip-
tional profiling of peripheral blood cells. The first is to use
whole blood. This can be stabilized at the time of blood
draw against RNA degradation and further transcriptional
activation using proprietary reagents (eg, PAXgene RNA
tubes [Qiagen, Venlo, The Netherlands] and Tempus blood
RNA tubes [Applied Biosystems, Foster City, CA]) [15].
The advantage of investigating mRNA profiles stabilized at
the time of blood draw may be counteracted by the fact that
whole blood consists of a multitude of different cell types
that may be present in varying ratios in diseased compared
with control individuals and may consequently result in a
heterogeneous cell mixture. Variability in the blood transcrip-
tome may then indicate differences in cellular composition
138 Curr Psychiatry Rep (2010) 12:135–144rather than the underlying disease processes. Furthermore,
reticulocytes present in whole blood still have high levels of
hemoglobin mRNA; this represents about 70% of the mRNA
in whole blood. Globin mRNA has been shown to subdue
signals from other transcripts and result in noisy data [16];
procedures to remove it are advocated for some applications.
Isolation of specific cell subtypes from whole blood such
as peripheral blood monocytes, or even more specific
subgroups such as CD4
+ or CD8
+ T cells, requires
additional cell separation and purification steps. These have
been shown to alter gene expression by inducing several
cell-stress–related genes due to prolonged handling or by
activating certain receptor-specific pathways if subtypes are
selected using antibodies against certain surface receptors
[17]. The third option is to use lymphoblastoid cell lines.
Although these have been shown to be a good representa-
tion of the in vivo state [18], expression patterns of specific
genes may be affected by the Epstein-Barr virus infection
that is necessary for their transformation [19]. Lympho-
blastoid cell lines may also exhibit extreme clonality (ie, a
situation in which most cells in a culture derive from the
same single-cell ancestor) with random patterns of mono-
allelic expression in single clones [20].
Although the use of a single cell type reduces the range
of factors influencing gene expression, thus increasing the
power for genetic investigations [18, 21], expression
profiles may be confounded by changes in gene expression
d u et oh a n d l i n ga n dt r a n s f o r mation. In addition, the
relatively complex procedures necessary for isolating single
cell types are often impractical for very large cohorts.
Therefore, in practice, many studies rely on whole blood
RNA collection tubes that can be easily used for data
collection in large cohorts.
Animal Brain Tissue
Animal tissue is often the only realistic option as a tissue source
for examining brain-related gene expression changes. In
animals, postmortem delay is much shorter and can be held
constantforallexperimentalgroups.Geneexpressionstudiesin
inbred animal strains can identify gene expression changes in a
homogeneous genetic background, with the signal not masked
by the noise generated from the variable genetic background
present in human studies [22•]. Furthermore, several inducible
gene expression systems have been developed in transgenic
animals that allow expression of certain genes of interest in
distinct brain regions to be turned on and off [23]. These
animals represent powerful tools that enable detailed studies of
the impact of individual genes on gene expression.
Optimal animal models for major depression, however,
have not been developed yet, undoubtedly at least partly due
to the intrinsically human nature of these complex behavioral
phenotypes. One approach has been to focus on certain
behavioral or endocrinologic dimensions of major depression
that can be modelled in animals but do not necessarily
represent the complexity of the disorder in humans. In
addition, as described for human postmortem studies, neurons
within a given brain region exhibit a very heterogeneous
expression of neurotransmitters, receptors, and connections to
other brain regions, likely leading to differential alterations of
gene expression and modifications in neighboring neurons
after exposure to the same stimulus. As for the human brain,
cell type–specific dissection may be required [24].
Overall, there is no optimal tissue for examining gene
expression changes related to MD, and we must weigh the
advantages and disadvantages of each option for a specific
research question.
The National Institutes of Health recently proposed an
ambitious Genotype-Tissue Expression project, a database
that will include expression analysis from 30 different
tissues in 1,000 samples. In addition, the National Center
for Biotechnology Information has initiated the Gene
Expression Omnibus, a gene expression/molecular abun-
dance repository (http://www.ncbi.nlm.nih.gov/geo/index.
cgi) supporting high-quality data submissions from research
groups worldwide. This curated online resource for gene
expression allows data browsing, query, and retrieval in
gene expression datasets from human and experimental
animals, different tissue types, and different diseases, as
well as physiologic states.
Expression Array Studies in Major Depression
Transcriptional Profiling in Postmortem Brain Tissue
Large variability exists in the type of brain regions investi-
gated in postmortem gene expression studies for MD. The
investigated brain regions include the amygdala, anterior
cingulate cortex [25-27••], prefrontal and orbitofrontal cortex
regions [28-30], and hippocampus and hypothalamus
[31, 32], all of which have been implicated in the
pathophysiology of MD through animal and brain imaging
studies. Transcriptional profiles of different brain regions
show substantial differences [27••, 29], making comparisons
between profiles derived from various brain regions difficult.
Even if the same regions are chosen, the proportion of
neurons and glia that make up the final cells for RNA
extraction remains mostly undetermined, and this may
underlie some of the conflicting results from MD gene
expression studies. A possible alternative is LCM, as
described previously, which allows selection of specific cell
types for RNA extraction. Wang et al. [33] used LCM to
analyze mRNA from neurons in the paraventricular nucleus
of the hypothalamus in postmortem tissue from patients with
MD compared with that of controls. With a qPCR candidate
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140 Curr Psychiatry Rep (2010) 12:135–144gene approach, they observed an upregulation of genes
activating the hypothalamus-pituitary-adrenal axis (including
the corticotropin-releasing hormone and its receptor
[CRHR1] and NR3C2 encoding the mineralocorticoid
receptor) and downregulation of inhibiting genes (eg,
androgen receptor). This was specific to neurons in the
paraventricular nucleus and not observed in neurons of the
supraoptic nucleus, underlining the importance of cell and
region specificity in these analyses.
Genome-wide approaches, including transcriptomics,
using microarrays carry the risk of false-positive associations
due to the high number of performed tests. To reduce the
number of reported false-positive associations, Sibille et al.
[27••] used data from postmortem tissue, as well as an
animal model. The authors reported an mRNA signature
derived from the amygdala of depressed patients that was
validated in an animal model of unpredictable chronic mild
stress. In both approaches, genes implicated in oligodendro-
cyte structure and function were downregulated, whereas
genes associated with neuronal enrichment were upregulated.
This molecular signature was reversed in the stress model by
antidepressive treatment. Alterations in oligodendroglial
abnormalities were also shown in the temporal cortex of
depressed individuals by Aston et al. [34].
Several other studies investigated gene expression
changes in postmortem tissue of patients with MD, with
or without suicide (Table 1). The most consistent findings
were differences in expression of genes associated with
glutamatergic and γ-aminobutyric acid–ergic function [25,
26, 29, 35].
Transcriptional Profiling With RNA From Peripheral
Blood Cells
Toourknowledge,onlyonemicroarraystudyhasinvestigated
depression using RNA from peripheral white blood cells at a
genome-wide level. Segman and colleagues [36] found
gene expression signatures that could differentiate between
women prone to postpartum depression. These differential
signatures were characterized by differences in immune
activation and decreased transcriptional engagement in cell
proliferation, DNA replication, and repair processes. All
other studies have analyzed candidate genes using qPCR
methods, the results of which often have been inconsistent or
could not be replicated by other groups (Table 2).
For example, Iga et al. [37] observed an increase in
vascular endothelial cell growth factor mRNA in peripheral
leukocytes with MD that was reversed after psychophar-
macologic treatment, but this finding could not be replicated
at the protein level [38]. Serotonin transporter (5-HTT)
mRNA was shown to be increased in patients with MD in
two reports [39, 40] but reduced in another [41].
Transcriptional Profiling in Animal Models of Major
Depression
Several different animal models for depression have been
investigated using microarrays, including animals subjected
to chronic stress or comparisons of behaviorally different
inbred rodent lines or transgenic animals. However, no
Table 2 Studies analyzing RNA from peripheral blood cells
Study Disorder RNA source RNA analysis Perturbed pathway
Segman et al. [36] Postpartum
depression
PBMCs Affymetrix Human
Exon 1.0
a
Reduced transcription and distinct
immune activation
Fujimoto et al. [50] Major depression Whole blood (QIAamp RNA
b) qPCR candidate genes Reduced glyoxalase-1 mRNA
Otsuki et al. [51] Major depression Whole blood (QIAamp RNA
b) qPCR candidate genes Reduced GDNF, ARTN, and
neurotrophin-3 mRNAs
Iga et al. [52] Major depression Whole blood (PAXgene
b) qPCR candidate genes Increased CREB and HDAC5
mRNAs
Iga et al. [37] Major depression Whole blood (PAXgene
b) qPCR candidate genes Increased VEGF mRNA
Matsubara et al. [53] Major depression Whole blood
(QIAamp RNA
b)
qPCR candidate genes Reduced GRα mRNA
Iga et al. [54] Major depression Whole blood (PAXgene
b) qPCR candidate genes Reduced LIM (PDLIM5) mRNA
Tsao et al. [40] Major depression PBMCs qPCR candidate genes Increased 5-HTT mRNA
Iga et al. [39] Major depression Whole blood (PAXgene
b) qPCR candidate genes Increased 5-HTT mRNA
Lima et al. [55] Major depression PBMCs qPCR candidate genes Reduced 5-HTT mRNA
aSanta Clara, CA
bQiagen, Venlo, The Netherlands
5-HTT serotonin transporter, CREB cyclic adenosine monophosphate response element-binding protein, GDNF glial cell line–derived
neurotrophic factor, PBMC peripheral blood mononuclear cell, qPCR quantitative polymerase chain reaction, VEGF vascular endothelial cell
growth factor
Curr Psychiatry Rep (2010) 12:135–144 141consistentresultshaveemergedfromthesestudies[23, 42-44].
This may be due to inherent differences in the stress
paradigms, animal strains, and brain-region specific alter-
ations. For example, Surget et al. [45] showed specific
transcriptome changes in different brain regions using the
unpredictable chronic mild stress paradigm, a model of
depression based on socioenvironmental stressors. Chronic
administration of two pharmacologically completely different
(putative) antidepressant drugs (fluoxetine and CRHR1
antagonist) reversed the behavioral effects and gene expres-
sion changes [45].
Convergent Functional Genomics
Each genome-wide molecular genetic approach bears a high
risk of false-positive associations. The combination of
results from several platforms to generate convergent
evidence may decrease the number of false-positive hits.
For example, Le-Niculescu et al. [22•] combined whole-
genome gene expression data from the whole blood of
bipolar patients with gene expression from the blood and
brain of a pharmacologic murine model of bipolar disorder,
as well as merged results from published genetic associa-
tion and linkage studies and published human postmortem
brain data. The authors identified five genes involved in
myelination and six genes involved in growth factor
signaling to show regulation and associations on all
required levels. Although this specific approach has
limitations, including the choice of the animal model
(valproate vs methamphetamine administration), the use of
convergent evidence may be a way in expression research
in psychiatric disorders to identify new candidate genes.
Conclusions
Overall, the dramatic technical advances in methods to
measure gene expression on a genome-wide level thus far
have not been paralleled by breakthrough discoveries in
MD using hypothesis-free approaches. This is due in part to
technical problems. Microarrays are only semiquantitative,
and their dynamic range may not be sufficiently sensitive to
detect relatively subtle gene expression differences in
psychiatric disorders. This problem may be solved by the
use of next-generation sequencing. In addition, access to
human brain tissue is difficult and only possible post-
mortem. Furthermore, it is still not clear whether it is
sufficient to investigate changes within a single brain region
or whether concerted changes in circuits have to be
analyzed. Cell type–specific dissections within a region
are likely necessary, but here again we lack the knowledge
as to exactly which cells in which region to select. Gene
expression changes in whole blood–derived mRNA can be
used as disease state or treatment response markers, but
they may not uncover major candidates directly involved in
the pathomechanism of MD. No single animal model for
major depression can claim full validity for the human
condition. In addition, MD itself is mostly a biologically
and genetically heterogeneous disorder. Studies relying on
case-control associations without further biological or
genetic stratification may never lead to consistent findings.
Adding risk genotypes and endophenotypes may help select
more homogeneous patient samples, which may increase
the chances of finding consistent gene expression profiles
for this disorder.
A next generation of gene expression experiments using
biological phenotyping of patients, convergent evidence
from animal models, brain-circuit related data analysis, and
next-generation sequencing will be needed to make
substantial progress in gene expression studies in MD.
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